0001493152-18-005445.txt : 20180418
0001493152-18-005445.hdr.sgml : 20180418
20180418214038
ACCESSION NUMBER: 0001493152-18-005445
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180416
FILED AS OF DATE: 20180418
DATE AS OF CHANGE: 20180418
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Williams Donald Allen
CENTRAL INDEX KEY: 0001620013
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-13789
FILM NUMBER: 18762390
MAIL ADDRESS:
STREET 1: C/O PRYOR CASHMAN LLP
STREET 2: 7 TIMES SQUARE
CITY: NEW YORK
STATE: NY
ZIP: 10036
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Marina Biotech, Inc.
CENTRAL INDEX KEY: 0000737207
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 112658569
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 17870 CASTLETON STREET
STREET 2: SUITE 250
CITY: CITY OF INDUSTRY
STATE: CA
ZIP: 91748
BUSINESS PHONE: 4259083600
MAIL ADDRESS:
STREET 1: 17870 CASTLETON STREET
STREET 2: SUITE 250
CITY: CITY OF INDUSTRY
STATE: CA
ZIP: 91748
FORMER COMPANY:
FORMER CONFORMED NAME: MDRNA, Inc.
DATE OF NAME CHANGE: 20080610
FORMER COMPANY:
FORMER CONFORMED NAME: NASTECH PHARMACEUTICAL CO INC
DATE OF NAME CHANGE: 19920703
4
1
form4.xml
X0306
4
2018-04-16
0
0000737207
Marina Biotech, Inc.
MRNA
0001620013
Williams Donald Allen
C/O MARINA BIOTECH, INC.
17870 CASTLETON STREET, SUITE 250
CITY OF INDUSTRY
CA
91748
1
0
0
0
Series E Convertible Preferred Stock
0.50
2018-04-16
4
A
0
18
5000
A
2018-04-16
common stock
180000
18
D
Warrants to Purchase Common Stock
0.55
2018-04-16
4
A
0
135000
0.00
A
2018-04-16
common stock
135000
135000
D
In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the "Offering"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 18 shares of Series E Preferred Stock and warrants to purchase 135,000 shares of common stock.
Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock.
The warrants expire on the five year anniversary of the closing of the Offering.
/s/ Donald A. Williams
2018-04-18